Newly Diagnosed Prostate Cancer
Radical Prostatectomy
PROTEUS: A Study of ERLEADA (Apalutamide) in Participants With High‑Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
Phase: 3
Study Product: Apalutamide with ADT vs. ADT with placebo
Estimated Study Completion Date: April 22, 2024
ClinicalTrials.gov Identifier: NCT03767244
PSA Relapse
MAP: Muscadine Plus (MPX) In Men With Prostate Cancer
Phase: 3
Study Product: Muscadine Plus
Estimated Study Completion Date: December 2021
ClinicalTrials.gov Identifier: NCT03535675
MCSPC
KEYNOTE-991: Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Phase: 3
Study Product: pembrolizumab plus enzalutamide plus ADT vs. placebo plus enzalutamide plus ADT
Estimated Study Completion Date: September 1, 2026
ClinicalTrials.gov Identifier: NCT04191096
MCSPC or MCRPC
Progressing on Abiraterone Acetate
DisperSol: A PK and Dose Escalation and Expansion Study of DST-2970 in Patients With Prostate Cancer With Rising PSA on Treatment With Abiraterone Acetate
Phase: 1
Study Product: Abiraterone Acetate plus Prednisone 5Mg Tab plus DST-2970 (Abiraterone)
Estimated Study Completion Date: July 31, 2022
ClinicalTrials.gov Identifier: NCT04291664
nmCRPC or MCRPC
DaroAct 20609: Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC)
Phase: 2b
Study Product: Darolutamide vs. Enzalutamide
Estimated Study Completion Date: December 31, 2022
ClinicalTrials.gov Identifier: NCT04157088
mCRPC
Treatment naïve
MAGNITUDE: A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
Phase: 3
Study Product: Niraparib with Abiraterone Acetate and Prednisone vs. Placebo with Abiraterone Acetate and Prednisone
Estimated Study Completion Date: July 21, 2022
ClinicalTrials.gov Identifier: NCT03748641
TALAPRO-2: Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
Phase: 3
Study Product: Talazoparib with Enzalutamide vs. Placebo with Enzalutamide
Estimated Study Completion Date: November 25, 2024
ClinicalTrials.gov Identifier: NCT03395197
Treatment naïve or post NHA
REFMAL 435: A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies
Phase: 1
Study Product: AZD4635 vs. AZD4635 with Durvalumab vs. AZD4635 with Abiraterone Acetate vs. AZD4635 with Enzalutamide
Estimated Study Completion Date: May 13, 2020
ClinicalTrials.gov Identifier: NCT03085095
AstraZeneca AZ5363: A Phase I, Open-label, Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination with Novel Agents in Patients with Metastatic Castration Resistant Prostate Cancer
Phase: 1
Study Product: Capivasertib with Abiraterone Acetate vs. Capivasertib with Enzalutamide
Estimated Study Completion Date: UNK
ClinicalTrials.gov Identifier: UNK
Post Abi, Enza, and/or Apa
QUEST: A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Phase: 1b/2
Study Product: Niraparib with JNJ-63723283 vs. Niraparib with Abiraterone Acetate
Estimated Study Completion Date: August 31, 2021
ClinicalTrials.gov Identifier: NCT03431350
Post Abi or Enza or Apa
KEYNOTE-921: Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Phase: 3
Study Product: Pembrolizumab with Docetaxel vs. Placebo with Docetaxel
Estimated Study Completion Date: February 28, 2023
ClinicalTrials.gov Identifier: NCT03834506
KEYNOTE-641: Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer
Phase: 3
Study Product: Pembrolizumab with Enzalutamide vs. Placebo with Enzalutamide
Estimated Study Completion Date: November 12, 2023
ClinicalTrials.gov Identifier: NCT03834493
Docetaxel Candidate
Modra: Study of ModraDoc006 with ritonavir (ModraDoc006/r) vs. I.V. Docetaxel in Metastatic Prostate Cancer
Phase: 2
Study Product: ModraDoc006/r vs. I.V. Docetaxel
Estimated Study Completion Date: April 1, 2021
ClinicalTrials.gov Identifier: NCT04028388
Post Chemotherapy
KEYLYNK-010: Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer
Phase: 3
Study Product: Pembrolizumab with Olaparib vs. Abiraterone Acetate or Enzalutamide
Estimated Study Completion Date: September 30, 2022
ClinicalTrials.gov Identifier: NCT03834519
GO27983: Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy
Phase: 2
Study Product: Ipatasertib
Estimated Study Completion Date: April 30, 2021
ClinicalTrials.gov Identifier: NCT01485861
Progressing on NHA (Abi or Enza)
ORIC-101-02: An Open-Label Phase 1b Study of ORIC-101 in Combination With Enzalutamide in Patients With Metastatic Prostate Cancer Progressing on Enzalutamide
Phase: 1b
Study Product: ORIC-101 vs. Enzalutamide
Estimated Study Completion Date: December 2022
ClinicalTrials.gov Identifier: NCT04033328
DST-2970-104: A Phase 1 PK and Dose Escalation and Expansion Study of DST-2970 in Patients With Prostate Cancer With Rising PSA on Treatment With Abiraterone Acetate
Phase: 1
Study Product: DST-2970
Estimated Study Completion Date: July 31, 2022
ClinicalTrials.gov Identifier: NCT04291664
Post Abi and/or Enza
Pfizer c2321001: PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Phase: 1
Study Product: PF-06821497
Estimated Study Completion Date: October 13, 2021
ClinicalTrials.gov Identifier: NCT03460977
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date. Please remember to talk to your healthcare providers first before making decisions about your plan of care.
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study. To learn more about our trials, call Jennifer at (843) 449-1010 ext. 316 or email us by filling out the form below.